Lincoln Capital Corp boosted its position in shares of Celgene Corporation (NASDAQ:CELG) by 5.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 30,395 shares of the biopharmaceutical company’s stock after purchasing an additional 1,544 shares during the quarter. Celgene Corporation comprises 3.4% of Lincoln Capital Corp’s holdings, making the stock its 7th biggest position. Lincoln Capital Corp’s holdings in Celgene Corporation were worth $3,782,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the business. Motco grew its position in shares of Celgene Corporation by 306.9% in the 1st quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 620 shares during the period. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Celgene Corporation in the 1st quarter valued at approximately $118,000. Oakworth Capital Inc. grew its position in shares of Celgene Corporation by 60.9% in the 1st quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after purchasing an additional 412 shares during the period. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in shares of Celgene Corporation by 47.5% in the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 380 shares during the period. Finally, WealthTrust Arizona LLC grew its position in shares of Celgene Corporation by 26.1% in the 1st quarter. WealthTrust Arizona LLC now owns 1,213 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 251 shares during the period. 79.43% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts recently issued reports on the company. Jefferies Group LLC reiterated a “buy” rating and issued a $160.00 price objective on shares of Celgene Corporation in a research report on Friday. Mizuho upped their price target on Celgene Corporation from $134.00 to $158.00 and gave the stock a “buy” rating in a research report on Friday. Royal Bank Of Canada initiated coverage on Celgene Corporation in a research report on Thursday. They set a “top pick” rating and a $176.00 price target for the company. Bank of America Corporation reaffirmed a “buy” rating on shares of Celgene Corporation in a research report on Wednesday. Finally, Cowen and Company reaffirmed a “buy” rating and set a $150.00 price target on shares of Celgene Corporation in a research report on Tuesday, September 12th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the company. Celgene Corporation presently has an average rating of “Buy” and a consensus target price of $149.34.
In other news, Director Michael D. Casey sold 9,250 shares of the company’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $125.59, for a total transaction of $1,161,707.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Gilla Kaplan sold 7,500 shares of the company’s stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total value of $1,008,900.00. Following the transaction, the director now directly owns 76,301 shares in the company, valued at $10,264,010.52. The disclosure for this sale can be found here. Insiders sold 267,476 shares of company stock valued at $35,812,841 in the last three months. 0.95% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: “Lincoln Capital Corp Purchases 1,544 Shares of Celgene Corporation (NASDAQ:CELG)” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://ledgergazette.com/2017/09/17/celgene-corporation-celg-shares-bought-by-lincoln-capital-corp-2.html.
Shares of Celgene Corporation (CELG) opened at 142.04 on Friday. The stock’s 50 day moving average price is $134.97 and its 200 day moving average price is $127.46. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $142.69. The company has a market cap of $111.12 billion, a P/E ratio of 43.99 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.21. The firm had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. Celgene Corporation’s quarterly revenue was up 18.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.44 earnings per share. On average, analysts forecast that Celgene Corporation will post $7.33 EPS for the current year.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.